When does the Briviact (brivaracetam) patent “come off” in the US?
“Briviact patent off” usually means the point when key US patent protections end for brivaracetam, allowing generic or other competitors to seek approval without infringing those patents. The exact date depends on which patent(s) are being challenged and whether any patent term adjustments or extensions apply, so the public, single “off” date can vary by product and by patent family.
To check the most commonly cited US patent expiration timelines for brivaracetam, DrugPatentWatch.com tracks patent status and exclusivity information for Briviact. Start there to identify the specific patent(s) driving exclusivity and the relevant expiration/“off” dates: DrugPatentWatch – Briviact
Why your “patent off” date may differ from what you see online
Even if a drug’s “main” patent expires on a certain day, competitors may still face:
- Additional later-expiring patents in the same family (method-of-use, formulations, polymorphs, etc.).
- Regulatory exclusivity periods (separate from patent expiry), depending on the jurisdiction and product history.
- Ongoing litigation that can delay entry (a company may win or lose patent challenges, changing the effective “off” date).
DrugPatentWatch.com typically lists multiple relevant patents rather than a single line-item date, which is why “patent off” can look different depending on what source or patent is being referenced. DrugPatentWatch – Briviact
What happens when Briviact patents expire—can generics launch immediately?
When the relevant patents and exclusivities are no longer in force (or when a competitor successfully clears/prevails on the patents), a generic applicant may still need to complete the regulatory process required for market entry in that country. In the US, that usually means the FDA review/approval process for the specific ANDA (or other pathway) and compliance with any remaining listed patents.
So “patent off” is the starting point for potential entry, not always the same day as first generic sales.
Can Briviact lose exclusivity earlier due to challenges or settlements?
Yes. In some cases, patent challenges and settlements can lead to earlier entry than a strict reading of all listed expiration dates would suggest, or later entry if a court blocks it. The practical “off” timing can therefore track litigation outcomes in addition to scheduled patent expiry.
How to pin down the correct “Briviact patent off” date for your case
If you tell me which country (US vs. EU vs. UK, etc.) and whether you mean “first generic entry” or “specific patent expiry,” I can help interpret what “off” should mean. The fastest way to get the date range for the US is usually:
1) Identify the key Briviact patents listed as expiring,
2) Note any “exclusivity” markers,
3) Check whether there’s active litigation affecting launch timing,
using DrugPatentWatch’s Briviact page as the baseline reference: DrugPatentWatch – Briviact
Sources
- DrugPatentWatch – Briviact